PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19925626-4	2010	Product labeling states that co-administration of an inhibitor of MAO-A (a MAOI-A) causes a 2-fold increase in sumatriptan plasma concentrations, and a 40% increase in elimination half-life.	Sumatriptan	111-122	monoamine oxidase A	Homo sapiens	66-71	
19925626-4	2010	Product labeling states that co-administration of an inhibitor of MAO-A (a MAOI-A) causes a 2-fold increase in sumatriptan plasma concentrations, and a 40% increase in elimination half-life.	Sumatriptan	111-122	monoamine oxidase A	Homo sapiens	75-81	
19925626-5	2010	OBJECTIVE: The objective of this study is to determine whether MAOI-A therapy should deter the use of 6 mg s.c. sumatriptan on pharmacokinetic grounds.	Sumatriptan	112-123	monoamine oxidase A	Homo sapiens	63-69	
19925626-16	2010	The dominance of the distribution phase and completeness of absorption of a 6 mg dose of s.c. sumatriptan explains the trivial effect size of the MAOI-A on plasma sumatriptan concentrations.	Sumatriptan	94-105	monoamine oxidase A	Homo sapiens	146-152	
19925626-16	2010	The dominance of the distribution phase and completeness of absorption of a 6 mg dose of s.c. sumatriptan explains the trivial effect size of the MAOI-A on plasma sumatriptan concentrations.	Sumatriptan	163-174	monoamine oxidase A	Homo sapiens	146-152	
12017403-2	2002	In vitro studies have suggested that sumatriptan is metabolized primarily by the monoamine oxidase-A isozyme and not by CYP3A4.	Sumatriptan	37-48	monoamine oxidase A	Homo sapiens	81-100	
8161354-4	1994	Incubation with clorgyline and deprenyl, probe inhibitors of MAO-A and MAO-B, respectively, showed that [14C]sumatriptan was metabolized by MAO-A; there was no evidence of P450 involvement in its metabolism.	Sumatriptan	109-120	monoamine oxidase A	Homo sapiens	61-66	
12190330-11	2002	Sumatriptan is metabolised by monoamine oxidase (MAO; predominantly the A isozyme, MAO-A) to an inactive metabolite.	Sumatriptan	0-11	monoamine oxidase A	Homo sapiens	83-88	
12190330-12	2002	Coadministration with a MAO-A inhibitor, moclobemide, leads to a significant increase in sumatriptan plasma concentrations and is contraindicated.	Sumatriptan	89-100	monoamine oxidase A	Homo sapiens	24-29	
9408857-3	1997	Through all species, the protein binding of sumatriptan is similar (14-16%), and its metabolic pathway undergoes extensive oxidative deamination involving the monoamine oxidase A isoenzyme.	Sumatriptan	44-55	monoamine oxidase A	Homo sapiens	159-178	
8161354-3	1994	The metabolism of [14C]sumatriptan was therefore investigated in vitro in a preparation derived from human liver, which was shown, by the use of the probe substrates [14C]testosterone (P450), [3H]5HT (MAO-A) and [14C]benzylamine (MAO-B) to be a rich source of both enzyme systems.	Sumatriptan	23-34	monoamine oxidase A	Homo sapiens	201-206	
8161354-4	1994	Incubation with clorgyline and deprenyl, probe inhibitors of MAO-A and MAO-B, respectively, showed that [14C]sumatriptan was metabolized by MAO-A; there was no evidence of P450 involvement in its metabolism.	Sumatriptan	109-120	monoamine oxidase A	Homo sapiens	140-145	
8161354-5	1994	The data in this study therefore indicate that the enzyme MAO-A is the major enzyme responsible for the metabolism of sumatriptan in human liver.	Sumatriptan	118-129	monoamine oxidase A	Homo sapiens	58-63